Even though a previous trial showed a significant reduction of CRP levels in the AP group (p-value = 0.023), compared to placebo, (10) and a recent case report of CRP apheresis showed successful outcomes in seven severe COVID-19 patients, (18) further RCTs are needed before concluding the impact of AP on CRP and its role as a therapeutic target in COVID-19. Here, CRP is linked to alkaline phosphatase measurement.